Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer

By Pharmaceutical Processing | May 12, 2010

WuXi PharmaTech (Cayman) Inc. has appointed Hao Zhou as Chief Financial Officer, effective immediately.

Mr. Zhou joined the company in May 2009 as Vice President of Finance. His initial responsibilities included financial planning and analysis, ERP system enhancement, tax, and treasury, and he has assumed increasing responsibilities for overall financial operations. As Chief Financial Officer, Hao will report to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

Prior to joining WuXi PharmaTech, Mr. Zhou worked for eleven years at General Electric. He held positions of increasing responsibility in financial planning and analysis, enterprise resource planning (ERP) systems, accounting and internal control at GE and was based in Tokyo, London, Shanghai, and several locations in the United States. Most recently he was Finance Director, Greater China, for GE Healthcare Medical Diagnostics and Life Sciences. He also served as an auditor for GE Corporate.

“I am very pleased to announce Hao’s promotion to Chief Financial Officer,” commented Dr. Ge Li. “With his strong financial background and work ethic, Hao has done an excellent job managing our company’s financial operations.

“I also want to thank Ed Hu for serving as a very effective acting Chief Financial Officer for the past year, in addition to his other responsibilities. Hao’s appointment allows Ed to concentrate on building our operations and growing our business as our Chief Operating Officer.”

Edward Hu, Chief Operating Officer, commented, “I have worked closely with Hao over the past year. He has demonstrated the keen intellect, strong financial expertise, and diligence required of a Chief Financial Officer. I look forward to working with him as WuXi continues to build its capabilities.”

Dr. Li concluded, “We look forward to Hao’s financial leadership as our growing company broadens its platform of R&D services for the world’s pharmaceutical, biotechnology, and medical device companies and prepares to combine with Charles River Laboratories.”

 

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE